Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.

Código QR

Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.

<h4>Background</h4>The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaopeng Dong, Yingtao Hao, Yucheng Wei, Qiuwei Yin, Jiajun Du, Xiaogang Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5191222fd2fd4354ac4b64cd90488992
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
por: Ioannis Boukovinas, et al.
Publicado: (2008)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Youwen Zhu, et al.
Publicado: (2021)

Survival of an elderly patient with lung cancer treated with first-line chemotherapy
por: Oscar Augusto Quintana Blancos, et al.
Publicado: (2021)

Survival of an elderly patient with lung cancer treated with first-line chemotherapy
por: Oscar Augusto Quintana Blancos, et al.
Publicado: (2021)

Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.
por: Yung-Che Chen, et al.
Publicado: (2013)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
por: Qiao Liu, et al.
Publicado: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Qiao Liu, et al.
Publicado: (2021)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Christian Möhring, et al.
Publicado: (2021)

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
por: Man He, et al.
Publicado: (2021)

A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
por: Jun Zhou, et al.
Publicado: (2013)

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
por: Wenxiao Jiang, et al.
Publicado: (2021)

“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
por: Mingqi Wang, et al.
Publicado: (2021)

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
por: Gupta N, et al.
Publicado: (2013)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Hao-chuan Ma, et al.
Publicado: (2021)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Hong Jian, et al.
Publicado: (2017)

S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
por: Ming-ming He, et al.
Publicado: (2013)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Jie Zhang PhD, et al.
Publicado: (2021)

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
por: Jin F, et al.
Publicado: (2016)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021)

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients
por: Jia-Jia Cui, et al.
Publicado: (2017)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Ze-Rui Zhao, et al.
Publicado: (2021)

The influence of genetic polymorphisms on the toxicity of platinum-based chemotherapy in the treatment of non-small cell lung cancer
por: Spasić Jelena, et al.
Publicado: (2021)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
por: Minami S, et al.
Publicado: (2015)

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami S, et al.
Publicado: (2016)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Wallace Akerley, et al.
Publicado: (2021)

Rrm2b deletion causes mitochondrial metabolic defects in renal tubules
por: Yi-Fan Chen, et al.
Publicado: (2019)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Chia-I Shen, et al.
Publicado: (2021)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Yawen Zheng, et al.
Publicado: (2021)

Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy
por: Katrina Kildey, et al.
Publicado: (2021)

Preliminary comparison of neuropsychological performance in patients with non-small-cell lung cancer treated with chemotherapy or targeted therapy
por: Kang HL, et al.
Publicado: (2019)

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
por: Joy C. Hsu, et al.
Publicado: (2021)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021)

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis
por: Li-Ming Tan, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
por: Yuanyi Cai, et al.
Publicado: (2021)

Low Concentrations of Dehydroepiandrosterone Sulfate are Associated with Depression and Fatigue in Patients with Non-Small-Cell Lung Cancer After Chemotherapy
por: Fang YH, et al.
Publicado: (2020)